A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

December 4, 2024

Study Completion Date

March 4, 2025

Conditions

Advanced/Metastatic Solid Tumors

Interventions

BIOLOGICAL

HLX53

There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion.

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY